|
|
Volumn 96, Issue 2, 2003, Pages 66-69
|
|
Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care
b
b,c
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
OSELTAMIVIR;
SIALIDASE INHIBITOR;
ZANAMIVIR;
ACETAMIDE DERIVATIVE;
ANTIVIRUS AGENT;
GUANIDINE DERIVATIVE;
PYRAN DERIVATIVE;
SIALIC ACID DERIVATIVE;
SIALIDASE;
ADOLESCENT;
ADULT;
AGED;
ARTICLE;
CONSULTATION;
COST BENEFIT ANALYSIS;
DATA ANALYSIS;
DRUG COST;
EPIDEMIC;
EVALUATION;
HEALTH CARE COST;
HUMAN;
INFLUENZA;
MAJOR CLINICAL STUDY;
PHYSICIAN;
PRESCRIPTION;
PRIMARY MEDICAL CARE;
RISK;
STATISTICAL MODEL;
STATISTICS;
SYMPTOM;
VACCINATION;
CHILD;
CLINICAL TRIAL;
DRUG ANTAGONISM;
ECONOMICS;
GENERAL PRACTICE;
MIDDLE AGED;
MULTICENTER STUDY;
NATIONAL HEALTH SERVICE;
PATIENT ATTITUDE;
UNITED KINGDOM;
ACETAMIDES;
ADOLESCENT;
ADULT;
AGED;
ANTIVIRAL AGENTS;
CHILD;
FAMILY PRACTICE;
GREAT BRITAIN;
GUANIDINES;
HUMANS;
INFLUENZA, HUMAN;
MIDDLE AGED;
NEURAMINIDASE;
OSELTAMIVIR;
PATIENT ACCEPTANCE OF HEALTH CARE;
PYRANS;
SIALIC ACIDS;
STATE MEDICINE;
ZANAMIVIR;
|
|
EID: 0037313615
PISSN: 01410768
EISSN: None
Source Type: Journal
DOI: 10.1258/jrsm.96.2.66 Document Type: Article |
|
Times cited : (4)
|
|
References (9)
|
